• Vaccine Name: Actinobacillus pleuropneumoniae HS93Tox-/pIG-T1K vectored vaccine
• Target Pathogen: Actinobacillus pleuropneumoniae
• Target Disease: porcine pleuropneumonia
• Vaccine Ontology ID: VO_0004607
• Type: Recombinant vector vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Mice
• Vector:
  • Vector name:
  • VO vector ID: VO_0001038
• Preparation: The HS93Tox- mutant of the serovar 7 strain of Actinobacillus pleuropneumoniae lacks the genes encoding the toxin ApxA and the post-translational activating protein ApxC, but still has genes required for secretion, making it a good vector. A plasmid vector was created to express the ApxA gene inside the HS93Tox- mutant of A. pleuropneumoniae, so that the bacterium acts as a vector for its own natural toxin (Prideaux et al., 1998).
• Immunization Route: Intramuscular injection (i.m.)
• Virulence: Because the toxin has been attenuated, this greatly decreases the potential virulence of the vaccine.
• Description: The HS93Tox-/pIG-T1K vector strain, using an Actinobacillus pleuropneumoniae to express the AxpA gene, was shown to protect mice against Actinobacillus pleuropneumoniae challenges (Prideaux et al., 1998). ApxA gene encodes an A. pleuropneumoniae structural toxin (Prideaux et al., 1998).

Mouse Response

• Vaccine Immune Response Type: VO_0001030
• Immune Response: The inoculation with HS93Tox-/pIG-T1K induced antibodies specific to the Apx gene, and this response was boosted when the mice were re-inoculated (Prideaux et al., 1998).
• Challenge Protocol: The mice inoculated with HS93Tox-/pIG-T1K strain expressing the toxin gene and the HS93Tox- not expressing the toxin gene were challenged with homologous wild-type serovar 7 and heterologous serovar 1 strains of A. pleuropneumoniae (Prideaux et al., 1998).
• Efficacy: The mice vaccinated with the HS93Tox-/pIG-T1K strain were protected against both the serovar 7 and serovar 1 challenges, but the mice only inoculated with the HS93Tox- strain not expressing the gene for the AxpA toxin received no protection against the heterologous serovar 1 challenge (Prideaux et al., 1998).